Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colloidal bismuth pectin is an orally administered gastric mucosal protectant consisting of a compositionally non-stoichiometric complex of pectin and bismuth. In the acidic stomach environment, it forms a viscous colloidal layer that adheres preferentially to injured or inflamed gastric mucosa, helping shield the surface from acid and pepsin and supporting mucus secretion and mucosal repair. It also has local anti-Helicobacter pylori activity and is used in bismuth-containing eradication regimens with acid suppression and antibiotics. The substance is minimally systemically absorbed; formulations are used for chronic gastritis, peptic-ulcer disease, and related upper-gastrointestinal symptoms. ([ypk.39.net](https://ypk.39.net/861396/manual/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colloidal bismuth pectin.